Catheter-Related Bloodstream Infection (CRBSI) Market Size, Share, and Growth Forecast 2026 - 2033

The global Catheter-Related Bloodstream Infection (CRBSI) market size is expected to be valued at US$1.5 billion in 2026 and is projected to reach US$2.1 billion by 2033, growing at a CAGR of 4.6% between 2026 and 2033, driven by the increasing use of central venous catheters, rising incidence of healthcare-associated infections, and greater emphasis on patient safety and infection control.

The Catheter-Related Bloodstream Infection (CRBSI) market encompasses products and technologies designed to prevent, diagnose, and manage bloodstream infections associated with intravascular catheters. The market includes antimicrobial catheters, catheter securement devices, disinfectants, antiseptics, diagnostic solutions, and infection prevention products used across hospitals, intensive care units, and dialysis centers.

Drivers - Hospital-Acquired Infection Prevention Mandates Reinforce Antimicrobial Catheter Adoption

Regulatory agencies and healthcare accreditation bodies continue tightening hospital-acquired infection prevention standards, reinforcing demand for antimicrobial catheters and integrated securement systems across intensive care and dialysis settings. The Centers for Disease Control and Prevention continues to classify central line-associated bloodstream infections among the most preventable healthcare-associated conditions, sustaining regulatory pressure on hospitals to adopt comprehensive infection prevention bundles.

The World Health Organization continues documenting substantial mortality and cost burden associated with catheter-related bloodstream infections across intensive care unit patients globally, reinforcing hospital administrator prioritization of antimicrobial-coated catheter procurement. Companies, including Becton, Dickinson and Company (BD) and Teleflex Incorporated, continue expanding antimicrobial catheter portfolios featuring chlorhexidine and silver-impregnated coatings designed to reduce colonization risk. This sustained regulatory and clinical emphasis on infection prevention continues reinforcing procurement volume for antimicrobial catheter and securement device manufacturers across hospital and dialysis center channels worldwide throughout the current forecast period.

Expanding Dialysis Patient Population Strengthens Vascular Access Device Demand

Growing global chronic kidney disease prevalence continues expanding the population of patients requiring long-term vascular access for hemodialysis, sustaining demand for antimicrobial catheters and infection prevention products tailored to dialysis center settings. The International Society of Nephrology continues documenting substantial global chronic kidney disease burden, with a meaningful share of affected patients eventually requiring dialysis access via central venous catheters during treatment initiation or as a long-term modality.

Dialysis patients face elevated catheter-related bloodstream infection risk relative to general hospital populations, given repeated catheter access during recurring treatment sessions. Companies including Nipro Corporation and Baxter International Inc. continue expanding dialysis-specific catheter and disinfectant portfolios addressing this elevated infection risk profile. This sustained expansion of the global dialysis patient population continues reinforcing procurement volume for antimicrobial catheters, securement devices, and diagnostic testing solutions across dialysis center channels throughout the current forecast period.

Restraints - High Cost of Antimicrobial Catheter Technology Limits Broader Adoption

Antimicrobial-coated catheters carry substantially higher per-unit cost relative to conventional uncoated catheter alternatives, restraining adoption among cost-constrained healthcare facilities and price-sensitive regional markets. Hospitals operating within constrained procurement budgets frequently default to conventional catheter alternatives paired with manual infection prevention protocols rather than premium antimicrobial-coated devices, particularly across smaller community hospitals and ambulatory surgical centers lacking dedicated infection prevention budgets.

Reimbursement policy variation across regional healthcare systems further complicates consistent antimicrobial catheter adoption, as insurers occasionally decline to differentiate reimbursement rates between standard and antimicrobial-coated catheter categories. This cost sensitivity continues to limit broader antimicrobial catheter penetration across price-sensitive healthcare facilities and emerging market healthcare systems lacking dedicated infection prevention capital allocation throughout the current forecast period.

Inconsistent Infection Prevention Protocol Adherence Limits Product Effectiveness

Catheter insertion and maintenance protocol adherence varies substantially across healthcare facilities, limiting the real-world effectiveness of antimicrobial catheters and securement devices relative to their demonstrated clinical trial performance. The Centers for Disease Control and Prevention continues to document persistent gaps in central line insertion bundle compliance across intensive care units, particularly during high-patient-volume periods when staffing constraints limit strict protocol adherence.

Smaller healthcare facilities and long-term care settings frequently lack dedicated infection prevention personnel capable of maintaining consistent catheter care protocol compliance relative to well-resourced academic medical centers. This protocol adherence variability continues limiting the demonstrated clinical benefit of premium antimicrobial catheter and securement device adoption, occasionally leading procurement committees to question return on investment relative to conventional catheter and manual protocol alternatives across resource-constrained healthcare settings.

Opportunities - Rapid Diagnostic Testing Innovation Strengthens Early Infection Detection

Rapid diagnostic testing technology presents a substantial commercial opportunity for manufacturers seeking to differentiate offerings beyond conventional antimicrobial catheter and securement device categories. Companies including Becton, Dickinson and Company (BD) and ICU Medical, Inc. continue advancing rapid molecular diagnostic platforms capable of identifying catheter-related bloodstream infection pathogens within hours rather than the multi-day turnaround associated with conventional blood culture methods.

The U.S. Food and Drug Administration continues clearing novel rapid diagnostic panels through expedited regulatory pathways, validating continued innovation within this category. Diagnostic Tests represent the fastest-expanding product-type segment within the global market, reflecting clinician preference for rapid pathogen identification supporting faster targeted antibiotic therapy initiation. This growth trajectory positions diagnostic technology developers to capture accelerating demand across hospital intensive care units and dialysis centers seeking to reduce infection-related morbidity and length of hospital stay throughout the coming forecast years.

Dialysis Center Expansion across Emerging Markets Strengthens Product Demand

Expanding dialysis center infrastructure across emerging healthcare markets presents a substantial opportunity for antimicrobial catheter and infection prevention product manufacturers seeking geographic diversification beyond mature hospital markets. Government-backed healthcare infrastructure investment across Asia Pacific and Latin America continues to support dialysis center capacity expansion, addressing growing chronic kidney disease patient populations requiring long-term vascular access.

Companies, including Nipro Corporation and Fresenius Kabi AG, continue expanding dialysis-specific product portfolios and regional distribution partnerships to serve this growing infrastructure base. Dialysis Centers represent an accelerating end-user segment within the global market, positioning manufacturers that prioritize cost-efficient antimicrobial catheter and disinfectant solutions to capture incremental demand across price-sensitive emerging market dialysis infrastructure. This expansion trajectory continues to create substantial incremental demand for infection prevention products tailored to resource-constrained dialysis center settings throughout the current forecast period.

Product Type Analysis

Antimicrobial catheters are expected to maintain the dominant product-type position, commanding a 39% share of global revenue in 2026, a position anchored by widespread hospital adoption of chlorhexidine and silver-impregnated catheter technology designed to reduce central line-associated bloodstream infection incidence. Hospitals and dialysis centers continue prioritizing antimicrobial catheter procurement because clinical evidence consistently shows reduced colonization and infection rates compared with conventional uncoated catheter alternatives.

The Centers for Disease Control and Prevention continues to reinforce antimicrobial catheter adoption as a recommended infection prevention practice within central line insertion bundles across intensive care units. Companies including Becton, Dickinson and Company (BD), B. Braun SE, and Teleflex Incorporated continue expanding antimicrobial catheter portfolios to address diverse vascular access applications across hospital and dialysis center settings. Diagnostic Tests represent the fastest-expanding product-type segment, propelled by rapid molecular diagnostic innovation supporting faster pathogen identification, reinforcing antimicrobial catheter dominance as the foundational product category across the global CRBSI prevention and management market.

End-user Analysis

Hospitals are expected to maintain the dominant end-user position, accounting for an estimated 62% share of global revenue in 2026, a position anchored by concentrated intensive care unit patient populations requiring central venous catheterization for extended treatment durations. Hospitals continue serving as the primary treatment setting for critically ill patients at elevated catheter-related bloodstream infection risk, sustaining demand for antimicrobial catheters, securement devices, disinfectants, and diagnostic testing across intensive care, surgical, and general medical units.

Companies, including Cardinal Health, Inc. and Medline Industries, LP, continue prioritizing hospital-focused distribution strategies given concentrated purchasing authority within centralized hospital procurement systems. Dialysis centers represent the fastest-expanding end-user segment, supported by growing global chronic kidney disease prevalence and expanding dialysis infrastructure investment across emerging markets, reinforcing hospital dominance as the primary channel for comprehensive infection prevention product adoption while dialysis centers capture accelerating incremental demand across long-term vascular access management applications.

North America CRBSI Market Trends and Insights

North America is anticipated to command the leading regional position within the global CRBSI market, holding a 35% share in 2026, anchored by stringent hospital-acquired infection prevention regulation, high intensive care unit bed capacity, and concentrated presence of leading manufacturers including Becton, Dickinson and Company (BD) and 3M Company.

Regulatory oversight administered through the Centers for Disease Control and Prevention continues mandating comprehensive infection prevention bundle compliance across hospital intensive care units, reinforcing sustained antimicrobial catheter and diagnostic testing adoption. Sustained healthcare infrastructure investment and favorable reimbursement frameworks administered through the Centers for Medicare & Medicaid Services continue supporting premium antimicrobial catheter procurement across hospital and dialysis center settings, positioning North America as the primary innovation hub driving global CRBSI prevention technology adoption throughout the current forecast period.

U.S. CRBSI Market Size

The U.S. CRBSI market value is set to reach an estimated US$452 million in 2026, propelled by concentrated intensive care unit capacity and sustained hospital infection prevention budget allocation supported by favorable Centers for Medicare & Medicaid Services reimbursement policy for antimicrobial catheter and diagnostic testing procurement.

Leading manufacturers, including Becton, Dickinson and Company (BD), Teleflex Incorporated, and ICU Medical, Inc., maintain significant domestic research and manufacturing operations, reinforcing continuous product innovation cycles across antimicrobial catheter and rapid diagnostic technology categories. Growing dialysis patient populations requiring long-term vascular access, combined with sustained hospital infection prevention regulatory oversight, continues to reinforce the position of the U.S. as the largest single national contributor to global CRBSI market revenue throughout the current forecast period.

Europe CRBSI Market Trends and Insights

Europe sustains steady CRBSI market expansion, supported by regulatory harmonization across European Medicines Agency member states and established infection prevention reimbursement pathways for antimicrobial catheters and diagnostic testing products. Germany anchors regional demand through robust hospital infrastructure and sustained manufacturing presence of companies including B. Braun SE, headquartered domestically.

National Health Service systems across the U.K., France, and other member states continue prioritizing infection prevention capital investment supporting antimicrobial catheter and securement device adoption, reinforcing steady procurement volume growth across hospital and dialysis center channels. Growing dialysis center networks and expanding intensive care unit capacity across the region continue supporting sustained demand for advanced infection prevention technology, positioning Europe as a mature yet steadily expanding regional market throughout the current forecast period.

Germany CRBSI Market Size

The Germany CRBSI market value is likely to reach an estimated US$105 million in 2026, propelled by robust hospital infrastructure and the domestic headquarters presence of B. Braun SE, a leading antimicrobial catheter and infusion therapy manufacturer. Federal health insurance reimbursement frameworks continue supporting hospital investment in antimicrobial catheter and diagnostic testing procurement across German intensive care units and dialysis centers.

Sustained chronic kidney disease prevalence across the German population, combined with continuous research collaboration between device manufacturers and academic medical centers, reinforces Germany’s position as the leading national contributor to European regional revenue, supporting continuous product validation and clinical evidence generation throughout the current forecast period.

U.K. CRBSI Market Size

The U.K. CRBSI market value is predicted to reach an estimated US$78 million in 2026, supported by National Health Service infection prevention investment programs prioritizing antimicrobial catheter adoption across designated intensive care and dialysis units. Academic medical centers affiliated with leading British universities continue maintaining research partnerships supporting clinical validation of emerging antimicrobial catheter and rapid diagnostic technology.

Growing dialysis patient referral volume through specialized National Health Service renal networks continues reinforcing demand for advanced vascular access infection prevention products. Sustained government commitment toward hospital-acquired infection reduction targets, combined with concentrated clinical expertise across London and other major medical centers, continues to support steady market expansion throughout the current forecast period across the United Kingdom.

France CRBSI Market Size

France CRBSI market value is anticipated to reach an estimated US$62 million in 2026, anchored by robust public healthcare infrastructure and sustained government investment supporting university hospital intensive care unit expansion. Regulatory alignment through CE marking frameworks continues to facilitate streamlined commercialization of antimicrobial catheter and diagnostic testing products across French academic medical centers.

Growing dialysis center networks affiliated with national nephrology associations continue reinforcing demand for infection prevention technology supporting long-term vascular access management. Sustained collaboration between French infection control societies and device manufacturers continues to support continuous clinical evidence generation, reinforcing France's position as a steady contributor to broader European regional market revenue throughout the current forecast period.

Asia Pacific CRBSI Market Trends and Insights

Asia Pacific is expected to register the fastest regional growth trajectory within the global CRBSI market, propelled by expanding hospital infrastructure, rising healthcare expenditure, and growing chronic kidney disease prevalence across populous economies. China anchors regional demand through sustained hospital infrastructure expansion and government healthcare reform initiatives that broaden access to advanced infection prevention technology across urban and rural populations alike.

Domestic device manufacturers and multinational companies, including Nipro Corporation, continue expanding regional manufacturing and distribution presence to serve growing dialysis and intensive care patient volume. Rising chronic kidney disease incidence across the region's aging populations, combined with expanding dialysis center infrastructure investment, continues reinforcing Asia Pacific's position as the fastest-expanding regional market throughout the current forecast period.

India CRBSI Market Size

The India CRBSI market value is expected to reach an estimated US$55 million in 2026, propelled by expanding tertiary hospital infrastructure and growing government healthcare investment supporting advanced infection prevention product accessibility across urban centers. The Ministry of Health and Family Welfare continues supporting healthcare infrastructure expansion programs that broaden access to specialized dialysis and intensive care services beyond metropolitan hospitals.

Growing dialysis center capacity, combined with expanding private hospital investment in antimicrobial catheter and diagnostic testing technology, continues reinforcing India's position among the fastest-expanding national markets within the Asia Pacific region, supporting sustained procurement demand throughout the current forecast period across both public and private healthcare sectors.

The global CRBSI competitive landscape presents a moderately consolidated structure, with established medical device conglomerates competing alongside specialized infection prevention and diagnostic technology developers across antimicrobial catheter, securement device, disinfectant, and diagnostic testing segments. Market leaders including Becton, Dickinson and Company (BD), B. Braun SE, and 3M Company pursue expansion through continuous research and development investment, strategic acquisitions of specialized diagnostic technology developers, and academic medical center research partnerships supporting clinical evidence generation.

Companies including Teleflex Incorporated and ICU Medical, Inc. continue leveraging broad vascular access portfolios to cross-sell antimicrobial catheters alongside securement devices and diagnostic testing solutions. Emerging business models emphasize bundled infection prevention program contracts and rapid diagnostic platform licensing arrangements, positioning diagnostic innovation and clinical evidence strength as increasingly decisive competitive differentiators alongside traditional manufacturing reliability.

Key Industry Developments:

• In June 2025, Becton, Dickinson and Company (BD) launched the BD IntraSight™ Vascular Access System, an integrated central line insertion solution designed to enhance patient safety and improve procedural efficiency.
• In May 2024, the World Health Organization (WHO) published its first global guidelines for preventing bloodstream infections associated with peripheral intravenous catheters. The guidance includes 14 good practice statements and 23 evidence-based recommendations covering healthcare worker training, aseptic techniques, catheter insertion and maintenance, catheter selection, and timely removal.